Parallel Advisors
ESPR icon

Parallel Advisors’s Esperion Therapeutics ESPR Stock Holding History

Parallel Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818 Sell
259
-95,995
-100% -$269K ﹤0.01% 3721
2026
Q1 		$264K Sell
96,254
-10,430
-10% -$33K ﹤0.01% 1011
2025
Q4 		$395K Sell
106,684
-10,740
-9% -$34.7K 0.01% 775
2025
Q3 		$311K Sell
117,424
-10,000
-8% -$19.3K 0.01% 855
2025
Q2 		$125K Buy
127,424
+117,424
+1,174% +$118K ﹤0.01% 1246
2025
Q1 		$14.4K Hold
10,000
– – ﹤0.01% 2290
2024
Q4 		$22K Sell
10,000
-234,000
-96% -$546K ﹤0.01% 2101
2024
Q3 		$403K Buy
244,000
+5,000
+2% +$10.1K 0.01% 642
2024
Q2 		$531K Hold
239,000
– – 0.01% 521
2024
Q1 		$641K Sell
239,000
-239,000
-50% -$581K 0.02% 456
2023
Q4 		$1.43M Hold
478,000
– – 0.04% 268
2023
Q3 		$468K Buy
+478,000
New +$692K 0.02% 474
2023
Q2 		– Sell
-169
Closed -$269 – 3414
2023
Q1 		$269 Buy
+169
New +$872 ﹤0.01% 3245
2022
Q4 		– Sell
-53
Closed – – 3404
2022
Q3 		$0 Buy
53
+18
+51% +$124 ﹤0.01% 3240
2022
Q2 		$0 Buy
+35
New +$198 ﹤0.01% 3081
2022
Q1 		– Sell
-1,526
Closed -$8K – 3050
2021
Q4 		$8K Buy
1,526
+1,400
+1,111% +$11.2K ﹤0.01% 2195
2021
Q3 		$2K Buy
126
+124
+6,200% +$1.8K ﹤0.01% 2674
2021
Q2 		$0 Hold
2
– – ﹤0.01% 2963
2021
Q1 		$0 Sell
2
-3
-60% -$89 ﹤0.01% 2821
2020
Q4 		$0 Sell
5
-5
-50% -$150 ﹤0.01% 2599
2020
Q3 		$0 Buy
+10
New +$396 ﹤0.01% 2585
2020
Q2 		– Sell
-17,710
Closed -$558K – 2513
2020
Q1 		$558K Hold
17,710
– – 0.05% 225
2019
Q4 		$1.06M Buy
17,710
+10,000
+130% +$450K 0.08% 176
2019
Q3 		$283K Buy
+7,710
New +$305K 0.02% 388
2019
Q2 		– Sell
-2,000
Closed -$80K – 2345
2019
Q1 		$80K Buy
+2,000
New +$89.7K 0.01% 685

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Parallel Advisors's ESPR Position: Q2 2026 in Review

Parallel Advisors reduced its Esperion Therapeutics (ESPR) stake by 100% in Q2 2026, selling an estimated $269K and leaving 259 shares worth $818. The position accounts for ﹤0.01% of the portfolio, ranked #3721.

Parallel Advisors first reported a position in ESPR in Q1 2019 and has held it in 25 quarters since. The position peaked at $1.43M in Q4 2023. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Parallel Advisors held 259 shares of Esperion Therapeutics worth $818 as of Q2 2026.
  • Parallel Advisors sold 95,995 Esperion Therapeutics shares in Q2 2026, an estimated $269K.
  • Esperion Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3721 holding.
  • Parallel Advisors first reported a position in Esperion Therapeutics in Q1 2019 and has held it in 25 quarters since.
  • Parallel Advisors's Esperion Therapeutics position peaked at $1.43M in Q4 2023.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.